Europe’s Phase I trials see Spain, U.K. lead hot spots

While the U.K. has been on the biotech map for some time, Spain is emerging as a hot spot for clinical trials in Phase I — an area moving into focus as the need for speed in generating early human data takes on new importance. Across Europe, hot spots for clinical trials vary by disease area, with I&I activity distributed across the broadest set of countries.

BioCentury’s analysis of European Phase I trials in 2021-25 found that Spain’s strength was especially pronounced in cancer and rare diseases, while the U.K. led in immunology & inflammation (I&I) and neurology, and Germany led endocrine and metabolic trials. ...